CoChat
Sign Up
Cited by 113

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Recent developments in the regulation of the angiogenic switch by cellular stress factors in tumors

North, Sophie, Moenner, Michel, Bikfalvi, Andreas·2005·Cancer Letters
DOI 10.1016/j.canlet.2004.08.007
Open this paper in CoChat — free account

Abstract

Angiogenesis in tumors is controlled by the so-called 'angiogenic switch' which allows the passage from low invasive and poorly vascularized tumors to highly invasive and angiogenic tumors. A number of cellular stress factors such as hypoxia, nutrient deprivation or inducers of reactive oxygen species (ROS) are important stimuli of angiogenic signalling. The HIF system plays a significant role in several of these effects and the molecular mechanisms of its regulation have recently been characterized. In addition, HIF-independent mechanisms have been described which involved number of other molecules and transcription factors such as nuclear factor-(kappa)B (NF-(kappa)B) and p53. p53 is an important intracellular mediator of the stress response and is now also recognized as a modifier of the angiogenic response. p53 may interact with the HIF system but may also have direct effects on angiogenesis regulators or interfere with translation mechanisms of angiogenesis factors.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.canlet.2004.08.007

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 13 references

Research works printed but not linked: 111

  1. Abe, 2002, Hypoxia and HIF-1alpha stability: another stress-sensing mechanism for Shc, Circ. Res., 91, 4, 10.1161/01.RES.0000026654.65882.55 · DOI
  2. Adler, 1999, Role of redox potential and reactive oxygen species in stress signaling, Oncogene, 18, 6104, 10.1038/sj.onc.1203128 · DOI
  3. Aladjem, 1998, ES cells do not activate p53-dependent stress responses and undergo p53-independent apoptosis in response to DNA damage, Curr. Biol., 8, 145, 10.1016/S0960-9822(98)70061-2 · DOI
  4. Allen, 2000, Oxidative stress and gene regulation, Free Radic. Biol. Med., 28, 463, 10.1016/S0891-5849(99)00242-7 · DOI
  5. Ambartsumian, 2001, The metastasis-associated Mts1(S100A4) protein could act as an angiogenic factor, Oncogene, 20, 4685, 10.1038/sj.onc.1204636 · DOI
  6. An, 1998, Stabilization of wild-type p53 by hypoxia-inducible factor 1alpha, Nature, 392, 405, 10.1038/32925 · DOI
  7. Arbiser, 2002, Reactive oxygen generated by Nox1 triggers the angiogenic switch, Proc. Natl Acad. Sci. USA, 99, 715, 10.1073/pnas.022630199 · DOI
  8. Atsumi, 2002, High expression of inducible 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (iPFK-2; PFKFB3) in human cancers, Cancer Res., 62, 5881
  9. Bardos, 2004, Growth factor-mediated induction of HDM2 positively regulates hypoxia-inducible factor 1alpha expression, Mol. Cell. Biol., 24, 2905, 10.1128/MCB.24.7.2905-2914.2004 · DOI · Paper page
  10. Bian, 1997, Transcriptional activation by p53 of the human type IV collagenase (gelatinase A or matrix metalloproteinase 2) promoter, Mol. Cell. Biol., 17, 6330, 10.1128/MCB.17.11.6330 · DOI
  11. Bikfalvi, 2002, Recent advances in angiogenesis, anti-angiogenesis and vascular targeting, Trends Pharmacol. Sci., 23, 576, 10.1016/S0165-6147(02)02109-0 · DOI
  12. Blagosklonny, 1998, p53 inhibits hypoxia-inducible factor-stimulated transcription, J. Biol. Chem., 273, 11995, 10.1074/jbc.273.20.11995 · DOI
  13. Blouw, 2003, The hypoxic response of tumors is dependent on their microenvironment, Cancer Cell, 4, 133, 10.1016/S1535-6108(03)00194-6 · DOI · Paper page
  14. Bosca, 1986, Expression of the v-src or v-fps oncogene increases fructose 2,6-bisphosphate in chick-embryo fibroblasts. Novel mechanism for the stimulation of glycolysis by retroviruses, Biochem J., 236, 595, 10.1042/bj2360595 · DOI
  15. Brantley, 2002, Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo, Oncogene, 21, 7011, 10.1038/sj.onc.1205679 · DOI
  16. Brar, 2003, Redox signaling of NF-kappaB by membrane NAD(P)H oxidases in normal and malignant cells, Protoplasma, 221, 117, 10.1007/s00709-002-0059-y · DOI
  17. Brusselmans, 2001, Hypoxia-inducible factor-2alpha (HIF-2alpha) is involved in the apoptotic response to hypoglycemia but not to hypoxia, J. Biol. Chem., 276, 39192, 10.1074/jbc.C100428200 · DOI
  18. Burdon, 1990, Oxidative stress and tumour cell proliferation, Free Radic. Res. Commun., 11, 65, 10.3109/10715769009109669 · DOI
  19. Carmeliet, 2003, Angiogenesis in health and disease, Nat. Med., 9, 653, 10.1038/nm0603-653 · DOI
  20. Carmeliet, 2000, Angiogenesis in cancer and other diseases, Nature, 407, 249, 10.1038/35025220 · DOI · Paper page
  21. Christofori, 1994, Molecular dissection of multi-stage tumorigenesis in transgenic mice, Semin. Cancer Biol., 5, 3
  22. Dameron, 1994, Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1, Science, 265, 1582, 10.1126/science.7521539 · DOI
  23. Dames, 2002, Structural basis for Hif-1 alpha/CBP recognition in the cellular hypoxic response, Proc. Natl Acad. Sci. USA, 99, 5271, 10.1073/pnas.082121399 · DOI
  24. Denko, 2003, Investigating hypoxic tumor physiology through gene expression patterns, Oncogene, 22, 5907, 10.1038/sj.onc.1206703 · DOI
  25. Dohn, 2001, Receptor tyrosine kinase EphA2 is regulated by p53-family proteins and induces apoptosis, Oncogene, 20, 6503, 10.1038/sj.onc.1204816 · DOI
  26. Ema, 1999, Molecular mechanisms of transcription activation by HLF and HIF1alpha in response to hypoxia: their stabilization and redox signal-induced interaction with CBP/p300, Eur. Mol. Biol. Org. J., 18, 1905, 10.1093/emboj/18.7.1905 · DOI
  27. Eskey, 1993, Role of oxygen vs glucose in energy metabolism in a mammary carcinoma perfused ex vivo: direct measurement by 31P NMR, Proc. Natl Acad. Sci. USA, 90, 2646, 10.1073/pnas.90.7.2646 · DOI
  28. Ettinger, 2001, Urea as a recovery marker for quantitative assessment of tumor interstitial solutes with microdialysis, Cancer Res., 61, 7964
  29. Flamme, 1997, HRF, a putative basic helix-loop-helix-PAS-domain transcription factor is closely related to hypoxia-inducible factor-1 alpha and developmentally expressed in blood vessels, Mech. Dev., 63, 51, 10.1016/S0925-4773(97)00674-6 · DOI
  30. Folkman, 1971, Tumor angiogenesis: therapeutic implications, N. Engl. J. Med., 285, 1182, 10.1056/NEJM197111182852108 · DOI · Paper page
  31. Fukushima, 1998, Brain-specific angiogenesis inhibitor 1 expression is inversely correlated with vascularity and distant metastasis of colorectal cancer, Int. J. Oncol., 13, 967
  32. Galy, 2001, p53 directs conformational change and translation initiation blockade of human fibroblast growth factor 2 mRNA, Oncogene, 20, 4613, 10.1038/sj.onc.1204630 · DOI
  33. Galy, 2001, Tumour suppressor p53 inhibits human fibroblast growth factor 2 expression by a post-transcriptional mechanism, Oncogene, 20, 1669, 10.1038/sj.onc.1204271 · DOI
  34. Gatenby, 1995, The potential role of transformation-induced metabolic changes in tumor–host interaction, Cancer Res., 55, 4151
  35. Gautam, 2002, Aerosol delivery of PEI-p53 complexes inhibits B16-F10 lung metastases through regulation of angiogenesis, Cancer Gene Ther., 9, 28, 10.1038/sj.cgt.7700405 · DOI
  36. Golubovskaya, 2004, Cloning and characterization of the promoter region of human focal adhesion kinase gene: nuclear factor kappa B and p53 binding sites, Biochim. Biophys. Acta, 1678, 111, 10.1016/j.bbaexp.2004.03.002 · DOI
  37. Gorlach, 2001, Thrombin activates the hypoxia-inducible factor-1 signaling pathway in vascular smooth muscle cells: Role of the p22(phox)-containing NADPH oxidase, Circ. Res., 89, 47, 10.1161/hh1301.092678 · DOI
  38. Grigorian, 2001, Tumor suppressor p53 protein is a new target for the metastasis-associated Mts1/S100A4 protein: functional consequences of their interaction, J. Biol. Chem., 276, 22699, 10.1074/jbc.M010231200 · DOI
  39. Gullino, 1975, Extracellular compartments of solid tumors, vol. 3, 327
  40. Hainaut, 2000, p53 and human cancer: the first ten thousand mutations, Adv. Cancer Res., 77, 81, 10.1016/S0065-230X(08)60785-X · DOI
  41. Hansson, 2002, Two sequence motifs from HIF-1alpha bind to the DNA-binding site of p53, Proc. Natl Acad. Sci. USA, 99, 10305, 10.1073/pnas.122347199 · DOI
  42. Haskell, 2003, Focal adhesion kinase is expressed in the angiogenic blood vessels of malignant astrocytic tumors in vivo and promotes capillary tube formation of brain microvascular endothelial cells, Clin. Cancer Res., 9, 2157
  43. Helmlinger, 2002, Acid production in glycolysis-impaired tumors provides new insights into tumor metabolism, Clin. Cancer Res., 8, 1284
  44. Holmgren, 1998, p53 induces angiogenesis-restricted dormancy in a mouse fibrosarcoma, Oncogene, 17, 819, 10.1038/sj.onc.1201993 · DOI
  45. Iida, 2002, Vascular endothelial growth factor gene expression in a retinal pigmented cell is up-regulated by glucose deprivation through 3′ UTR, Life Sci., 71, 1607, 10.1016/S0024-3205(02)01842-8 · DOI
  46. Ikeda, 1995, Hypoxia-induced transcriptional activation and increased mRNA stability of vascular endothelial growth factor in C6 glioma cells, J. Biol. Chem., 270, 19761, 10.1074/jbc.270.34.19761 · DOI
  47. Javerzat, 2002, The role of fibroblast growth factors in vascular development, Trends Mol. Med., 8, 483, 10.1016/S1471-4914(02)02394-8 · DOI
  48. Jayaraman, 1997, Identification of redox/repair protein Ref-1 as a potent activator of p53, Genes Dev., 11, 558, 10.1101/gad.11.5.558 · DOI
  49. Kaufman, 2002, The unfolded protein response in nutrient sensing and differentiation, Nat. Rev. Mol. Cell Biol., 3, 411, 10.1038/nrm829 · DOI
  50. Kotch, 1999, Defective vascularization of HIF-1alpha-null embryos is not associated with VEGF deficiency but with mesenchymal cell death, Dev. Biol., 209, 254, 10.1006/dbio.1999.9253 · DOI
  51. Kuroki, 1996, Reactive oxygen intermediates increase vascular endothelial growth factor expression in vitro and in vivo, J. Clin. Invest., 98, 1667, 10.1172/JCI118962 · DOI
  52. Lando, 2000, A redox mechanism controls differential DNA binding activities of hypoxia-inducible factor (HIF) 1alpha and the HIF-like factor, J. Biol. Chem., 275, 4618, 10.1074/jbc.275.7.4618 · DOI
  53. Lawler, 2001, Thrombospondin-1 gene expression affects survival and tumor spectrum of p53-deficient mice, Am. J. Pathol., 159, 1949, 10.1016/S0002-9440(10)63042-8 · DOI
  54. Leker, 2004, The role of p53-induced apoptosis in cerebral ischemia: effects of the p53 inhibitor pifithrin alpha, Exp. Neurol., 187, 478, 10.1016/j.expneurol.2004.01.030 · DOI
  55. Levy, 1995, Transcriptional regulation of the rat vascular endothelial growth factor gene by hypoxia, J. Biol. Chem., 270, 13333, 10.1074/jbc.270.22.13333 · DOI
  56. Levy, 1998, Hypoxic stabilization of vascular endothelial growth factor mRNA by the RNA-binding protein HuR, J. Biol. Chem., 273, 6417, 10.1074/jbc.273.11.6417 · DOI
  57. Linderholm, 2000, p53 and vascular-endothelial-growth-factor (VEGF) expression predicts outcome in 833 patients with primary breast carcinoma, Int. J. Cancer, 89, 51, 10.1002/(SICI)1097-0215(20000120)89:1<51::AID-IJC9>3.0.CO;2-8 · DOI
  58. Lu, 2004, Kigamicin D, a novel anticancer agent based on a new anti-austerity strategy targeting cancer cells' tolerance to nutrient starvation, Cancer Sci., 95, 547, 10.1111/j.1349-7006.2004.tb03247.x · DOI
  59. Marjon, 2004, Expression of the pro-angiogenic factors vascular endothelial growth factor and interleukin-8/CXCL8 by human breast carcinomas is responsive to nutrient deprivation and endoplasmic reticulum stress, Mol. Cancer, 3, 4, 10.1186/1476-4598-3-4 · DOI
  60. Mazurek, 2003, The tumor metabolome, Anticancer Res., 23, 1149
  61. Minchenko, 2002, Hypoxia-inducible factor-1-mediated expression of the 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 (PFKFB3) gene. Its possible role in the Warburg effect, J. Biol. Chem., 277, 6183, 10.1074/jbc.M110978200 · DOI
  62. Mukhopadhyay, 1995, Wild-type p53 and v-Src exert opposing influences on human vascular endothelial growth factor gene expression, Cancer Res., 55, 6161
  63. Nishimori, 1997, A novel brain-specific p53-target gene, BAI1, containing thrombospondin type 1 repeats inhibits experimental angiogenesis, Oncogene, 15, 2145, 10.1038/sj.onc.1201542 · DOI
  64. Oren, 2003, Decision making by p53: life, death and cancer, Cell Death Differ., 10, 431, 10.1038/sj.cdd.4401183 · DOI
  65. Ozawa, 2001, Regulation of tumor angiogenesis by oxygen-regulated protein 150, an inducible endoplasmic reticulum chaperone, Cancer Res., 61, 4206
  66. Pan, 2004, p53 cannot be induced by hypoxia alone but responds to the hypoxic microenvironment, Oncogene, 23, 4975, 10.1038/sj.onc.1207657 · DOI
  67. Park, 2001, Hypoglycemia-induced VEGF expression is mediated by intracellular Ca2+ and protein kinase C signaling pathway in HepG2 human hepatoblastoma cells, Int. J. Mol. Med., 7, 91
  68. Park, 2003, Hypoxia-induced gene expression occurs solely through the action of hypoxia-inducible factor 1alpha (HIF-1alpha): role of cytoplasmic trapping of HIF-2alpha, Mol. Cell. Biol., 23, 4959, 10.1128/MCB.23.14.4959-4971.2003 · DOI
  69. Piret, 2002, Is HIF-1alpha a pro- or an anti-apoptotic protein?, Biochem. Pharmacol., 64, 889, 10.1016/S0006-2952(02)01155-3 · DOI
  70. Pluquet, 2001, Genotoxic and non-genotoxic pathways of p53 induction, Cancer Lett., 174, 1, 10.1016/S0304-3835(01)00698-X · DOI
  71. Reddy, 2003, Endoplasmic reticulum chaperone protein GRP78 protects cells from apoptosis induced by topoisomerase inhibitors: role of ATP binding site in suppression of caspase-7 activation, J. Biol. Chem., 278, 20915, 10.1074/jbc.M212328200 · DOI · Paper page
  72. Richard, 1999, p42/p44 mitogen-activated protein kinases phosphorylate hypoxia-inducible factor 1alpha (HIF-1alpha) and enhance the transcriptional activity of HIF-1, J. Biol. Chem., 274, 32631, 10.1074/jbc.274.46.32631 · DOI
  73. Ryan, 1998, HIF-1 alpha is required for solid tumor formation and embryonic vascularization, Eur. Mol. Biol. Org. J., 17, 3005, 10.1093/emboj/17.11.3005 · DOI · Paper page
  74. Sabapathy, 1997, Regulation of ES cell differentiation by functional and conformational modulation of p53, Eur. Mol. Biol. Org. J., 16, 6217, 10.1093/emboj/16.20.6217 · DOI
  75. Satake, 1998, Up-regulation of vascular endothelial growth factor in response to glucose deprivation, Biol. Cell., 90, 161, 10.1016/S0248-4900(98)80337-7 · DOI
  76. Schafer, 2003, Oxidative stress regulates vascular endothelial growth factor-A gene transcription through Sp1- and Sp3-dependent activation of two proximal GC-rich promoter elements, J. Biol. Chem., 278, 8190, 10.1074/jbc.M211999200 · DOI
  77. Schmid, 2004, p300 relieves p53-evoked transcriptional repression of hypoxia-inducible factor-1 (HIF-1), Biochem. J., 380, 289, 10.1042/bj20031299 · DOI
  78. Schmidt-Hansen, 2004, Extracellular S100A4(mts1) stimulates invasive growth of mouse endothelial cells and modulates MMP-13 matrix metalloproteinase activity, Oncogene, 1
  79. Schmidt-Kastner, 1998, Absence of p53-dependent cell cycle regulation in pluripotent mouse cell lines, Oncogene, 16, 3003, 10.1038/sj.onc.1201835 · DOI
  80. Scortegagna, 2003, Multiple organ pathology, metabolic abnormalities and impaired homeostasis of reactive oxygen species in Epas1−/− mice, Nat. Genet., 35, 331, 10.1038/ng1266 · DOI · Paper page
  81. Seagroves, 2001, Transcription factor HIF-1 is a necessary mediator of the pasteur effect in mammalian cells, Mol. Cell. Biol., 21, 3436, 10.1128/MCB.21.10.3436-3444.2001 · DOI
  82. Sherif, 2001, Downmodulation of bFGF-binding protein expression following restoration of p53 function, Cancer Gene Ther., 8, 771, 10.1038/sj.cgt.7700361 · DOI
  83. Shono, 1996, Involvement of the transcription factor NF-kappaB in tubular morphogenesis of human microvascular endothelial cells by oxidative stress, Mol. Cell. Biol., 16, 4231, 10.1128/MCB.16.8.4231 · DOI
  84. Shweiki, 1995, Induction of vascular endothelial growth factor expression by hypoxia and by glucose deficiency in multicell spheroids: implications for tumor angiogenesis, Proc. Natl Acad. Sci. USA, 92, 768, 10.1073/pnas.92.3.768 · DOI · Paper page
  85. Sodhi, 2000, The Kaposi's sarcoma-associated herpes virus G protein-coupled receptor up-regulates vascular endothelial growth factor expression and secretion through mitogen-activated protein kinase and p38 pathways acting on hypoxia-inducible factor 1alpha, Cancer Res., 60, 4873
  86. Spitz, 2000, Glucose deprivation-induced oxidative stress in human tumor cells, Ann. NY Acad. Sci., 899, 349, 10.1111/j.1749-6632.2000.tb06199.x · DOI
  87. Stein, 1995, Stabilization of vascular endothelial growth factor mRNA by hypoxia and hypoglycemia and coregulation with other ischemia-induced genes, Mol. Cell. Biol., 15, 5363, 10.1128/MCB.15.10.5363 · DOI
  88. Stolle, 1998, Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene, Hum. Mutat., 12, 417, 10.1002/(SICI)1098-1004(1998)12:6<417::AID-HUMU8>3.0.CO;2-K · DOI
  89. Stubbs, 2003, Understanding the tumor metabolic phenotype in the genomic era, Curr. Mol. Med., 3, 49, 10.2174/1566524033361645 · DOI
  90. Subbaramaiah, 1999, Inhibition of cyclooxygenase-2 gene expression by p53, J. Biol. Chem., 274, 10911, 10.1074/jbc.274.16.10911 · DOI
  91. Sun, 2000, Wild type and mutant p53 differentially regulate the gene expression of human collagenase-3 (hMMP-13), J. Biol. Chem., 275, 11327, 10.1074/jbc.275.15.11327 · DOI
  92. Suzuki, 2001, Dephosphorylated hypoxia-inducible factor 1alpha as a mediator of p53- dependent apoptosis during hypoxia, Oncogene, 20, 5779, 10.1038/sj.onc.1204742 · DOI
  93. Szatrowski, 1991, Production of large amounts of hydrogen peroxide by human tumor cells, Cancer Res., 51, 794
  94. Takenaga, 1997, Increased expression of S100A4, a metastasis-associated gene, in human colorectal adenocarcinomas, Clin. Cancer Res., 3, 2309
  95. Tanimoto, 2000, Mechanism of regulation of the hypoxia-inducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein, Eur. Mol. Biol. Org. J., 19, 4298, 10.1093/emboj/19.16.4298 · DOI · Paper page
  96. Tian, 1998, The hypoxia-responsive transcription factor EPAS1 is essential for catecholamine homeostasis and protection against heart failure during embryonic development, Genes Dev., 12, 3320, 10.1101/gad.12.21.3320 · DOI · Paper page
  97. Tian, 1997, Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells, Genes Dev., 11, 72, 10.1101/gad.11.1.72 · DOI · Paper page
  98. Vargas, 2003, Mdm2: a regulator of cell growth and death, Adv. Cancer Res., 89, 1, 10.1016/S0065-230X(03)01001-7 · DOI
  99. Vaupel, 1989, Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review, Cancer Res., 49, 6449
  100. Walenta, 2002, Metabolic mapping with bioluminescence: basic and clinical relevance, Biomol. Eng., 18, 249, 10.1016/S1389-0344(01)00107-1 · DOI
  101. Warburg, 1956, On the origin of cancer cells, Science, 123, 309, 10.1126/science.123.3191.309 · DOI · Paper page
  102. Welsh, 2002, The redox protein thioredoxin-1 (Trx-1) increases hypoxia-inducible factor 1alpha protein expression: Trx-1 overexpression results in increased vascular endothelial growth factor production and enhanced tumor angiogenesis, Cancer Res., 62, 5089
  103. Xanthoudakis, 1992, Identification and characterization of Ref-1, a nuclear protein that facilitates AP-1 DNA-binding activity, Eur. Mol. Biol. Org. J., 11, 653, 10.1002/j.1460-2075.1992.tb05097.x · DOI · Paper page
  104. Xanthoudakis, 1994, The redox and DNA-repair activities of Ref-1 are encoded by nonoverlapping domains, Proc. Natl Acad. Sci. USA, 91, 23, 10.1073/pnas.91.1.23 · DOI
  105. Yasuda, 1999, Stimulation of in vitro angiogenesis by hydrogen peroxide and the relation with ETS-1 in endothelial cells, Life Sci., 64, 249, 10.1016/S0024-3205(98)00560-8 · DOI
  106. Yeldandi, 2000, Hydrogen peroxide generation in peroxisome proliferator-induced oncogenesis, Mutat. Res., 448, 159, 10.1016/S0027-5107(99)00234-1 · DOI
  107. Younes, 1996, Wide expression of the human erythrocyte glucose transporter Glut1 in human cancers, Cancer Res., 56, 1164
  108. Yu, 2002, Effect of p53 status on tumor response to antiangiogenic therapy, Science, 295, 1526, 10.1126/science.1068327 · DOI
  109. Zhang, 2000, Wild-type p53 suppresses angiogenesis in human leiomyosarcoma and synovial sarcoma by transcriptional suppression of vascular endothelial growth factor expression, Cancer Res., 60, 3655
  110. Ziegler, 2001, High glycolytic activity in rat glioma demonstrated in vivo by correlation peak 1H magnetic resonance imaging, Cancer Res., 61, 5595
  111. Elvert, 2003, Cooperative interaction of hypoxia-inducible factor-2α (HIF-2α) and Ets-1 in the transcriptional activation of vascular endothelial growth factor receptor-2 (Flk-1), J. Biol. Chem., 278, 7520, 10.1074/jbc.M211298200 · DOI

Cited by

Sorted by citations

Metadata

Authors
North, S., Moenner, M., & Bikfalvi, A.
Venue
Cancer Letters
Publisher
Elsevier BV
Published
2005-01
Volume
218
Issue
1
Pages
1-14
ISSN
0304-3835
DOI
10.1016/j.canlet.2004.08.007
Cited by
113
References
13
Language
en
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review